Eli Lilly’s value has surged on the back of its weight-loss and diabetes drugs, but more than 60% of revenue now comes from those products, leaving the company exposed if growth slows.
01Summary
- 01Chief executive Dave Ricks built Eli Lilly into the first $1 trillion pharma company.
- 02The company’s blockbuster weight-loss and diabetes drugs drove that rise.
- 03More than 60% of Eli Lilly’s revenue now comes from those drugs.
- 04The story says the drug giant faces the risks of its own success.
02Why it matters
Eli Lilly’s fortunes matter because its valuation and earnings are heavily tied to a narrow group of medicines. Any slowdown in demand or competitive pressure could affect one of the world’s most valuable pharmaceutical companies.
Pulse AIAsk about this story
Answers are generated by AI from the story summary; they are not investment, health or legal advice.
